
Opinion|Videos|April 8, 2025
Tildrakizumab in Practice: Adherence and Clinical Takeaways
Author(s)Aaron Farberg, MD
An expert discusses how health care provider administration may improve adherence to tildrakizumab. The meta-analysis confirms its real-world efficacy, safety, and quality of life benefits, supporting clinical use. These findings may influence payer decisions by reinforcing its value and long-term effectiveness in psoriasis care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Since tildrakizumab is administered by health care providers, do you think this leads to better adherence of the therapy?
- What are your main takeaways from this abstract, and how will you carry this over to your clinical practice?
- How do you believe these abstract results will influence payer decisions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5